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Enlarging Red Blood Cell Distribution Width During
Hospitalization Identifies a Very High-Risk Subset of Acutely
Decompensated Heart Failure Patients and Adds Valuable
Prognostic Information on Top of Hemoconcentration
Joa˜o Pedro Ferreira, MD, PhD, Nicolas Girerd, MD, PhD, Mattia Arrigo, MD,
Pedro Bettencourt Medeiros, MD, Miguel Bento Ricardo, MD, Tiago Almeida, MD,
Alexandre Rola, MD, Heli Tolpannen, MD, Said Laribi, MD, PhD, Etienne Gayat, MD, PhD,
Alexandre Mebazaa, MD, PhD, Christian Mueller, MD, PhD, Faiez Zannad, MD, PhD,
Patrick Rossignol, MD, PhD, and Irene Araga˜o, MD
Abstract: Red blood cell distribution width (RDW) may serve as an
integrative marker of pathological processes that portend worse prog-
nosis in heart failure (HF). The prognostic value of RDW variation
(DRDW) during hospitalization for acute heart failure (AHF) has yet to
be studied.
We retrospectively analyzed 2 independent cohorts: Centro Hospi-
talar do Porto (derivation cohort) and Lariboisie`re hospital (validation
cohort). In the derivation cohort a total of 170 patients (age 76.2 10.3
years) were included and in the validation cohort 332 patients were
included (age 76.4 12.2 years). In the derivation cohort the primary
composite outcome of HF admission and/or cardiovascular death
occurred in 78 (45.9%) patients during the 180-day follow-up period.
Discharge RDW and DRDWwere both increased when hemoglobin
levels were lower; peripheral edema was also associated with increased
discharge RDW (all P< 0.05). Discharge RDW value was significantly
associated with adverse events: RDW> 15% at discharge was associ-
ated with a 2-fold increase in event rate, HR¼ 1.95 (1.05–3.62),
P¼ 0.04, while a DRDW >0 also had a strong association with out-
come, HR¼ 2.47 (1.35–4.51), P¼ 0.003. The addition of both dis-
charge RDW> 15% and DRDW> 0 to hemoconcentration was
associated with a significant improvement in the net reclassification
index, NRI¼ 18.3 (4.3–43.7), P¼ 0.012. Overlapping results were
found in the validation cohort.
As validated in 2 independent AHF cohorts, an in-hospital RDW
enlargement and an elevated RDW at discharge are associated with
increased rates of mid-term events. RDW variables improve the risk
stratification of these patients on top of well-established prognostic
markers.
(Medicine 95(14):e3307)
Abbreviations: ACM = all-cause mortality, ADHF = acutely
decompensated heart failure, CVM = cardiovascular mortality, ER
= emergency room, Hb = hemoglobin, HF = heart failure, HR =
hazard ratio, IDI = integrated discrimination improvement, LVEF =
left ventricular ejection fraction, NP = natriuretic peptide, NRI =
net reclassification index, NT-pro BNP = N-terminal-pro brain
natriuretic peptide, RDW = red blood cell distribution width.
INTRODUCTION
R ed blood cell distribution width (RDW) is a measure of sizevariability in the red blood cell population (anisocytosis). Its
value is obtained by dividing the standard deviation of eryth-
rocyte volume by the mean corpuscular volume and multiplied
by 100 to express the result as a percentage.1 Disorders related
to ineffective erythropoiesis or increased red blood cell destruc-
tion cause greater heterogeneity in erythrocyte size and con-
sequently higher RDW.2,3 Hence, it has been advocated that
RDW may serve as an integrative measure of nutritional
deficiencies (e.g., iron and folate), bone marrow dysfunction,
and/or systemic inflammation, all of which are associated with
worse outcomes in heart failure (HF) patients.2,4 An elevated
RDW has been associated with mortality in several settings,
such as coronary artery disease, chronic HF, acute HF, stroke,
pulmonary hypertension, peripheral artery disease, critically ill
patients, and severe sepsis/septic shock.4–11 This finding is of
major interest since RDW is inexpensive and widely available
as part of the routine complete blood count.
Most studies have investigated the association of the RDW
value with outcome using a single baseline measurement (in
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various cohorts); however, much less is known regarding the
impact of the changes in RDW during hospitalization. In fact,
RDW may be considered as a dynamic variable with rapid
changes in acute disease states.10
Hemoconcentration (increase in hemoglobin and/or hem-
atocrit during hospitalization) has also been studied has a
possible target to assess decongestion in HF.12–18
To the best of our knowledge, no previous study has
addressed the dynamic changes of RDW in acutely decom-
pensated heart failure (ADHF). Furthermore, the relationship
between evolving RDW and hemoconcentration during hospi-
talization has yet to be tested.
We hypothesize that an increased RDW from baseline to
discharge can improve prognostic information in comparison to
discharge RDW alone, while increased RDWwithout hemocon-
centration may help to identify very high-risk ADHF patients.
METHODS
Studied Population, Emergency Room
Description, and Oversight
We analyzed 2 independent cohorts:
(1) Porto cohort (derivation cohort) – during a 3-year period
(from January 2012 to December 2014), all patients with
ADHF admitted to the emergency room (ER) of the tertiary
university hospital Centro Hospitalar do Porto (CHP),
Porto, Portugal, were retrospectively studied. This ER has
moreover certain noteworthy particularities. The ER is
situated within the Urgency Department under the super-
vision of the Intensive Care Unit. The ER is equipped with
ventilators and invasive monitoring devices in order to
receive unstable/severe patients. The patients described in
this cohort were all admitted for ADHF/pulmonary edema
with associated respiratory insufficiency (PaO2/FiO2< 300)
(2) Paris cohort (validation cohort) – during a 4-year period
(from January 2011 to December 2014), all patients with
dyspnea admitted to the urgency of the tertiary university
hospital Lariboisie`re, Paris, France, were prospectively
recorded in a uniform database, which was retrospectively
used for this study purposes, in which we selected only
those patients an ADHF diagnosis.
All authors designed the study. The 1st, 3rd, 4th, 5th, and
6th authors collected, recorded, and adjudicated the data. The
1st 2 authors performed the statistical analysis and wrote the 1st
draft of the manuscript. All authors edited and approved the
manuscript and assume full responsibility for the accuracy and
completeness of the data and for the fidelity of this report to the
study protocol.
Criteria and Definitions
Patients with ADHF criteria were included. The diagnosis
of ADHF was performed according to the European Society of
Cardiology (ESC) criteria, defined as a rapid or gradual onset of
signs and symptoms of worsening HF resulting in unplanned
hospitalization (including new onset acute HF).19,20 Associated
elevated natriuretic peptides (NPs) were used to adjudicate
hospitalization whenever possible (83.5% of cases in Porto
cohort and 96.4% of cases in Paris cohort). An echocardio-
graphic study was performed on all patients during the index
hospitalization. Left ventricular ejection fraction (LVEF) was
measured by Simpson biplane method. Patients with acute
myocardial infarction, systolic blood pressure <90mmHg,
mechanical cardiac support, chronic dialysis, and severe sepsis
were excluded in order to mitigate inclusion bias and obtain a
uniform dataset of severe ADHF patients – Figure 1.
Patient cases were recorded in a uniform database based on
the information collected from the clinical records/reports. The
study included cases from both community and referral hospi-
tals. Underlying diseases, precipitating factors, clinical presen-
tation, most recent echocardiography findings, and analytical
results (including hemoglobin, hematocrit, RDW, electrolytes,
plasma creatinine and urea, and NPs) were recorded at admis-
sion (i.e., first available data) and discharge (i.e., the last
available data). Blood analyses were performed using the Advia
2120 Hematology Analyzer (Siemens Healthcare Diagnostics,
Deerfield, IL) in CHP laboratory and Cell-Dyn Sapphire Ana-
lyser (ABBOTT Diagnosis) in Lariboisie`re laboratories. The
 
 
Patients admitted for ADHF + Respiratory Failure in the 
Emergency Room between January 2012 and December 2014 
(n=196) 
 
Patients excluded if presence of: 
- Acute myocardial infarction 
- Systolic blood pressure <90 mmHg 
- Mechanical cardiac support 
- Chronic dialysis 
- Severe sepsis. 
 
Final patients analyzed in this study 
(n=170) 
180-day follow-up 
- 78 (45.9%) patients had the composite outcome of 
hospitalization for ADHF or cardiovascular death 
Additionally excluded patients (n=26): 
- ADHF not confirmed 
- Repeated patients 
FIGURE 1. ADHF¼ acutely decompensated heart failure.
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RDW value is reported as a coefficient of variation (percentage)
of red blood cell volume. The normal reference range for RDW
in these hospital laboratories is 11.5% to 14.5% with intra- and
interassay variation coefficients of 3.6% and 6.5%, respectively.
The patients and/or their families who had been lost from
electronic registries were contacted in order to incorporate an
accurate, unbiased prognostic information.
In Porto cohort we studied 2 end-points: a composite
outcome of hospitalization for ADHF or cardiovascular
mortality (CVM) – whichever occurred first; and all-cause
mortality (ACM). In Paris cohort we studied ACM as primary
end-point, since the diagnosis for subsequent hospitalizations
was not adjudicated.
Hospital admission for ADHFwas defined according to the
most recent guidelines.21 The follow-up period was 180 days
starting from the hospital admission date.
The studywas carried out in accordancewith theDeclaration
of Helsinki and approved by the Institutional Ethics Committee.
The study flowchart for Porto cohort is provided in
Figure 1.
Statistical Analysis
The results are expressed asmean standard deviation (SD)
if the continuous variables had a normal distribution or as median
(percentile25–75) if the distribution was skewed. Normality
assumption was verified by visual discretion. Categorical vari-
ables are expressed as absolute numbers (n) and proportions (%).
The delta (D)RDWwascalculated as thedifference between
the last and first values dividedby the first (last first/first 100)
to account only for the actual difference between the 2 values.
DRDW 0 was considered as a decrease while DRDW> 0 was
considered as an increase. The first and last RDW were also
dichotomizedby rounded themedianvalue (15% inboth cohorts).
In Porto cohort, delta hemoglobin (Hb) was also calculated, with
DHb> 0 considered as a hemoconcentration, for example, an
increase in hemoglobin from admission to discharge, and
DHb 0 considered as no hemoconcentration, that is, a decrease
or no increase in hemoglobin from admission to discharge. In
Paris cohort, DHb was not calculated because discharge Hb
values were not available in the dataset.
Population characteristics were compared using the inde-
pendent sample t-test for normally distributed continuous vari-
ables, the Mann–WhitneyU-test for skewed variables, and Chi-
square tests for categorical variables.
Linear regression analyses were performed to assess the
linear association between RDW and determinants of clinical,
biochemical, therapeutic, and cardiovascular parameters. Can-
didate variables were chosen based on their a priori likeliness of
being associated with RDW after which a backward selection
was performed. Linearity and goodness of fit were verified.
Binary logistic regression analyses were also performed to
assess the associations of medications with dichotomic RDW.
The primary outcome was a composite of hospitalization
for ADHF or CVM in Porto cohort and ACM in Paris cohort.
Univariable time-to-event comparisons were made using the log
rank test and univariable Cox proportional hazards models.
Survival was estimated with the Kaplan–Meier method. Cox
proportional-hazards models were used to obtain unadjusted
and covariate adjusted hazard ratios (HRs). Proportional
hazards assumptions were verified, with covariates used for
adjusted HRs chosen from demographic, clinical, and labora-
tory variables that had been previously found to be clinically
relevant. All continuous variables included in the model were
verified for linearity.
The increased discriminative value associated with the
‘‘net reclassification improvement’’ (NRI) was assessed at
180 days.22,23 This method assesses the ability of a new model
to reclassify subjects with and without a clinical event during
follow-up. The ability of the new model to reclassify is sum-
marized by the NRI statistic. The continuous NRI method
developed by Uno23 and implemented in the survIDINRI pack-
age of the R software (The R Foundation for Statistical Com-
puting) was used. The continuous NRI method does not require
a prior definition of strata risk, thus considering the change in
the estimation prediction as a continuous variable. The inte-
grated discrimination improvement (IDI) was also calculated
and assesses the difference between the integrated sensitivity
gain and the integrated specificity loss due to the addition of the
studied estimator to the prognostic model.
Statistical analyses were performed using SPSS 23 soft-
ware (IBM Corp. Released 2013. IBM SPSS Statistics for
Windows, Version 23.0. Armonk, NY: IBM Corp.) and the R
software (The R Foundation for Statistical Computing).
A P value< 0.05 was considered statistically significant
(including for interaction).
RESULTS
Patient Characteristics
In Porto cohort a total of 170 patients were included. In this
cohort the mean SD age was 76.2 10.3 years. Half of the
patients were male, most had a history of hypertension history
(87.1%), diabetes mellitus was present in 52.9% of the patients,
and ischemic heart disease was the most frequent underlying
cause for HF (56.5%). The mean LVEF was 43.8 11.1% –
Table 1. The mean PaO2/FiO2 ratio was 165 86. At admission,
the vast majority of patients (98.8%) had signs of pulmonary
congestion as assessed by interstitial pulmonary edema on chest
X-ray, 54.7% had pleural effusion and 58.2% peripheral edema.
No significant differences between DRDW groups were found
with regard to clinical congestion markers at admission. How-
ever, at discharge, a trend for a higher proportion of patients with
peripheral edema was found in the DRDW >0 group (17.6 vs
31.5, P¼ 0.054). Patients with DRDW >0 had lower sodium,
albumin, hemoglobin, and hematocrit levels as well as higher N-
terminal-pro brain natriuretic peptide (NT-pro BNP), both at
admission and discharge (all P< 0.05). A trend toward lower
levels of serum iron during hospitalization was also found in
patients withDRDW>0 (54.9 32.4 vs 43.5 15.0, P¼ 0.082)
– Table 1.
The composite outcome of hospital admission for worsen-
ing HF and/or CVM occurred in 78 (45.9%) patients, and 43
(25.3%) subjects died from any cause during the 180-day
follow-up period – Table 1.
The baseline characteristics and events of Paris cohort are
presented in the Supplementary Material Table 1, http://
links.lww.com/MD/A883.
Factors Associated With RDW in Linear and
Logistic Regression Analysis
In Porto cohort higher admission and discharge RDW
levels were associated with lower levels of hemoglobin, hem-
atocrit, and transferrin saturation levels (all P< 0.05). The
presence of peripheral edema at discharge was also likely to
be associated with increased RDW (P< 0.05). The DRDW was
increased in association with a reduction in DHb (P< 0.05) –
Table 2.
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TABLE 1. Characteristics of the Study Population Globally and According to RDW Changes
Variables Total (n¼ 170) DRDW 0 (n¼ 103) DRDW >0 (n¼ 59) P-Value % Missing Values
Demographics and history
Age, years 76.2 10.3 75.0 9.9 77.5 10.58 0.150 0
Male sex – n, % 85 (50) 56 (54.4) 25 (43.1) 0.170 0
Hypertension – n, % 148 (87.1) 91 (88.2) 50 (86.3) 0.692 0
Diabetes mellitus – n, % 90 (52.9) 57 (55.3) 30 (51.7) 0.659 0
COPD – n, % 34 (20) 20 (21.7) 12 (24.0) 0.759 12.4
AFib – n, % 80 (47.1) 47 (45.6) 28 (48.3) 0.747 0
Heart failure characterization
Basal NYHA class 0.571 0
I – n, % 14 (8.2) 10 (9.7) 4 (6.9)
II – n, % 106 (62.4) 65 (63.1) 34 (58.6)
III – n, % 50 (29.4) 28 (27.2) 20 (34.5)
Ischemic etiology – n, % 96 (56.5) 57 (55.3) 34 (58.6) 0.687 0
LVEF, % 43.8 11.1 42.7 10.8 45.9 11.3 0.079 0
LVEF <40% – n, % 65 (38.2) 45 (43.7) 16 (27.6) 0.043
Beta-blockers–n, % 100 (58.8) 63 (61.2) 32 (55.2) 0.458 5.3
ACEi/ARBs – n, % 119 (70) 73 (70.9) 41 (70.7) 0.980 0
MRAs – n, % 23 (13.5) 12 (11.7) 9 (15.5) 0.484 0
Admission clinical assessment of congestion
Peripheral edema – n, % 99 (58.2) 56 (54.9) 38 (65.5) 0.190 0.6
Interstitial edema X-ray – n, % 168 (98.8) 101 (98.1) 58 (100) 0.286 0
Pleural effusion X-ray – n, (%) 93 (54.7) 58 (56.9) 30 (51.7) 0.530 0.6
PaO2/FiO2 ratio 165 86 155 78 177 92 0.116 0.6
Admission biochemical data
Urea, mg/dL 71.5 48.4 70.1 52.9 69.2 37.2 0.912 0
Creatinine, mg/dL 1.56 1.17 1.54 1.21 1.40 0.64 0.428 0
eGFR, mL/min/1.73m2 56.7 32.0 56.7 32.0 48.6 28.3 0.543 1.7
Sodium, mmol/L 137.5 5.1 138.6 4.0 135.7 6.4 0.001 0
Potassium, mmol/L 4.34 0.82 4.28 0.84 4.33 0.71 0.745 0
Albumin, mg/dL

3.6 0.6 3.7 0.5 3.4 0.6 0.001 25.9
Total protein, mg/dL

6.6 0.9 6.7 1.0 6.5 0.8 0.358 26.5
NT-pro BNP/100, pg/mL 38.8 (15.5–79.0) 28.8 (12.0–67.2) 54.4 (27.0–97.0) 0.001 16.5
Hemoglobin, g/dL 12.5 2.2 12.8 2.4 12.0 1.4 0.024 0.6
Hematocrit, % 38.7 5.9 39.5 6.2 37.3 5.2 0.024 0.6
RDW, % 15.4 2.7 15.6 3.1 15.0 1.6 0.105 0.6
RDW >15% – n, % 69 (40.6) 41 (39.8) 23 (39.7) 0.985
Serum iron, mg/dL

51.8 29.7 54.9 32.4 43.5 15.0 0.082 65.9
Ferritin, ng/mL

226 (107–453) 234 (139–465) 178 (94–414) 0.236 66.5
Transferrin saturation, %

16 (11–21) 16 (11–21) 16 (11–20) 0.718 67.1
Discharge clinical assessment of congestion
Peripheral edema – n, % 35 (20.6) 16 (17.6) 17 (31.5) 0.054 11.2
Interstitial edema X-ray – n, % 42 (24.7) 22 (34.9) 19 (40.4) 0.555 32.4
Pleural effusion – n, % 22 (12.9) 13 (14.1) 9 (14.3) 0.979 10.0
Discharge biochemical data
Urea, mg/dL 70.9 45.1 73.6 47.4 66.5 41.6 0.340 2.9
Creatinine, mg/dL 1.70 4.49 1.93 5.66 1.32 0.83 0.417 3.5
eGFR, mL/min/1.73m2 61.9 31.1 61.6 32.7 63.3 28.9 0.748 1.0
Sodium, mmol/L 139.7 4.3 139.6 4.3 139.6 4.2 0.959 2.4
Potassium, mmol/L 4.29 0.59 4.30 0.55 4.30 0.67 0.969 2.4
NT-pro BNP/100, pg/mL 60.3 (9.8–49.3) 15.6 (8.5–41.9) 23.6 (8.5–41.5) 0.021 25.9
Hemoglobin, g/dL 11.9 2.0 12.3 2.0 11.3 1.8 0.003 1.2
Hematocrit, % 36.8 5.5 37.7 5.7 35.5 5.1 0.015 2.9
RDW, % 15.1 2.1 14.6 1.9 15.9 2.2 <0.001 4.7
RDW >15% – n, % 58 (34.1) 26 (25.2) 32 (55.2) <0.001
DRDW, % 0.99 9.14 4.89 7.93 5.95 6.75 <0.001
Length of stay and events
Length of stay, days 11 (7–15) 10 (7–15) 13 (9–20) 0.010 0
180-day ACM – n, % 43 (25.3) 17 (16.5) 23 (39.7) 0.001 0
180-day CVM – n, % 29 (17.1) 10 (9.7) 16 (27.6) 0.003 0
180-day composite outcome – n, % 78 (45.9) 36 (35.0) 37 (63.8) <0.001 0
eGFR was calculated by the modified diet and renal disease (MDRD) formula. Bold, significant value (P 0.05). Composite outcome, includes the
first event of CVM or hospitalization for worsening heart failure. D¼ adjusted delta (discharge admission/admission 100). ACEi/
ARBs¼ angiotensin converting enzyme inhibitors/angiotensin receptor blockers, ACM¼ all-cause mortality, AFib¼ atrial fibrillation, COPD¼
chronic obstructive pulmonary disease, CVM¼ cardiovascular mortality, LVEF¼ left ventricular ejection fraction, MRA¼mineralocorticoid
receptor antagonist, n¼ number, NT-pro BNP¼N-terminal pro brain natriuretic peptide, NYHA¼New York Heart Association, RDW¼ red blood
cell distribution width.
Any measure during hospitalization.
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In Porto cohort, the odds of having admission RDW>15%
were increased by the presence of atrial fibrillation, and the odds
of having RDW >15% at discharge were increased by higher
RDW value at admission (both P< 0.05). The odds of having
DRDW >0 were significantly increased in patients with per-
ipheral edema at discharge – Table 3.
The factors associated with RDW values (both continuous
and categorical) in Paris cohort are presented in the Supple-
mentary Material Tables 2 and 3, http://links.lww.com/MD/
A883.
In Porto cohort admission, discharge and DRDW were
negatively correlated with the corresponding Hb values (Pear-
son correlation¼0.32, 0.42, and 0.25, respectively, all
P< 0.01) – Figure 2.
Association of RDW With Outcome
In Porto cohort, the RDW value (continuous and categ-
orical) at admission was not significantly associated with the
composite outcome of heart failure hospitalization or cardio-
vascular death. In contrast, discharge RDW value (continuous
and categorical >>15%) was significantly associated with
outcome. The last median RDW value >15% was indepen-
dently associated with composite outcome, even after stepwise
adjustment for potential confounders (sex, age, LVEF, atrial
fibrillation, the presence of peripheral edema, NT-pro BNP
level, sodium, urea, and Hb), whereas the last RDW as con-
tinuous variable did not remain significantly associated after
adjustment for the confounding variables included in model 3
(the presence of peripheral edema, NT-pro BNP level, sodium,
urea, and Hb) – Table 4 and Figure 3. Importantly, aDRDW>0
(i.e., an increase in the RDW value from admission to dis-
charge) had a strong independent association with outcome
(HR¼ 2.47 (1.35–4.51), P¼ 0.003, after adjustment for the
variables included in model 3) – Table 4 and Figure 3. The
strength of the association with the composite outcome was
magnified when considering patients with both discharge RDW
>15% andDRDW>0 (HR¼ 3.40 (1.63–7.08), P¼ 0.001, after
adjustment for the variables included in model 3) – Table 4 and
Figure 3. Considering ACM as outcome in Porto cohort, the
associations of discharge RDW (continuous), discharge RDW
>15%,DRDW>0, and discharge RDW>15% plusDRDW>0
together, were also positive and independently significant –
TABLE 2. Multiple Linear Regression Analysis of RDW at Admission, Discharge, and DRDW
Admission RDW Adjusted R2 Beta Intercept B (95% CI) Sd. Error P-Value
Overall model fit 0.22   2.92 <0.001
Constant   19.34 (16.78 to 21.90) 1.29 <0.001
Hemoglobin, g/dL 0.10 0.32 0.38 (0.55 to 0.21) 0.09 <0.001
Hematocrit, %

0.04 0.23 0.10 (0.17 to 0.04) 0.03 0.003
Transferrin saturation, % 0.08 0.31 0.09 (0.17 to 0.02) 0.04 <0.001
Discharge RDW
Overall model fit 0.75   1.09 <0.001
Constant   1.29 (3.22 to 5.80) 2.23 0.567
Admission RDW, % 0.32 0.57 0.45 (0.35 to 0.55) 0.05 <0.001
Hemoglobin, g/dL 0.17 0.42 0.44 (0.59 to 0.29) 0.08 <0.001
Hematocrit, %

0.07 0.28 0.11 (0.16 to 0.05) 0.03 <0.001
Transferrin saturation, % 0.05 0.25 0.07 (0.13 to 0.01) 0.03 0.064
Discharge peripheral edema, yes 0.02 0.17 0.84 (0.04 to 1.63) 0.40 0.039
DRDW
Overall model fit 0.28   7.78 <0.001
Constant   23.94 (31.13 to 16.75) 3.84 <0.001
Admission RDW, % 0.13 0.37 1.66 (2.13 to 1.20) 0.24 <0.001
DHemoglobin 0.06 0.25 13.62 (24.04 to 3.21) 5.27 0.011
Bivariate correlations were 1st assessed, after which the variables with significant correlations were entered in the linear regressionmodel in which a
backward selection was used. Only the final variables retained in the model are presented. In the admission RDWmodel, the following variables were
tested: age, sex, atrial fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-
ray (yes/no), urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro
BNP/100 (admission values were used unless stated otherwise). In the discharge RDW model, the following variables were tested: age, sex, atrial
fibrillation (yes/no), LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), admission
RDW, urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100
(discharge values were used whenever available). In theDRDWmodel, the following variables were tested: age, sex, atrial fibrillation (yes/no), LVEF,
peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no), pleural effusion on chest X-ray (yes/no), admission RDW, urea, creatinine,
sodium, potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100 (adjusted delta values
were used whenever available). Bold, significant value (P 0.05). D¼ adjusted delta (discharge–admission/admission). NT-pro BNP¼N-terminal
pro brain natriuretic peptide, RDW¼ red blood cell distribution width, Sd. Error¼ standard error.
Collinearity between hematocrit was found; however, hematocrit was forced in the final model to demonstrate that it also accounts for a significant
part of the RDW value (both at admission and discharge), but to a lesser extent than hemoglobin.
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Supplementary Material Table 6, http://links.lww.com/MD/
A883. Overlapping results were found in Paris cohort: the
associations of discharge RDW (continuous), discharge
RDW >15%, increasing DRDW, DRDW >0, and discharge
RDW >15% plus DRDW >0 together, were also positive and
independently associated with the outcome of ACM. Of notice,
in patients with both discharge RDW>15% and DRDW>0 the
association with outcome were particularly strong (HR¼ 3.82
(1.57–9.32), P¼ 0.003, after adjustment for the variables
included in model 2) – Supplementary Material Table 4,
http://links.lww.com/MD/A883.
Association of DRDW and Hemoconcentration
With Regard to Composite Outcome
In Porto cohort patients without hemoconcentration
(defined by a decrease in Hb from admission to discharge or
DHb 0) and DRDW >0, the association with adverse events
was very strong (HR¼ 4.98 [1.61–15.35], P¼ 0.005, after
adjustment for the variables included in model 3) – Table 4
and Figure 3. Of note, no significant interactions were found
between the studied RDW values and several independent
variables (including Hb). Hemoconcentration was not measured
in Paris cohort due to unavailability of discharge Hb in
the dataset.
Net Reclassification Indices
In Porto cohort, the increased discriminative value associ-
ated with the addition of RDW and hemoconcentration on top of
the covariates age, LVEF, Hb, creatinine, and NT-pro BNP at
admission was evaluated in order to predict the 180-day primary
composite outcome using NRI. The addition of the last RDW
>15% and DRDW >0 in the survival model was associated
with a significant improvement in reclassification (NRI¼ 23.1
[7.5–46.5], P¼ 0.013 and IDI¼ 8.2 [2.2–18.0], P< 0.001) –
Table 5 and Figure 4. Of note, the addition of the last RDW
>15% and DRDW >0 on top of the aforementioned variables
plus hemoconcentration was also associated with a significant
improvement in reclassification (NRI¼ 18.3 [4.3–43.7],
P¼ 0.012 and IDI¼ 7.8 [1.2–17.1], P< 0.001) – Table 5
and Figure 4. Discharge RDW>15% and DRDW >0 alone
also improved reclassification indices, whereas hemoconcen-
tration alone did not – Table 5. In Porto cohort, the increased
discriminative value associated with the addition of discharge
RDW, RDW >15% and DRDW >0 on top of a survival model
including the covariates age, LVEF, Hb, creatinine, and NT-pro
BNP at admission also significantly improved the net reclassi-
fication for 180-day ACM prediction (NRI for discharge RDW
continuous¼ 34.7 (2.0 to 50.0), P¼ 0.073; NRI for discharge
RDW>15%¼ 35.6 (3.6–55.1), P¼ 0.040; and NRI for DRDW
>0¼ 37.2 (6.0–55.4), P¼ 0.020) – Supplementary Material
Table 7, http://links.lww.com/MD/A883. Overlapping results
were found in Paris cohort – Supplementary Material Table 5,
http://links.lww.com/MD/A883.
TABLE 3. Multiple Logistic Regression Analysis of RDW (15
vs >15% at Admission and Discharge), DRDW (0 vs >0)
RDW>15% at Admission OR (95% CI) P-Value
Atrial fibrillation, yes 3.69 (1.89–7.19) <0.001
Hemoglobin, g/dL 0.80 (0.69–0.94) 0.006
RDW>15% at discharge
Admission RDW, % 2.75 (1.87–4.04) <0.001
Hemoglobin, g/dL 0.72 (0.56–0.93) 0.011
DRDW >0
Discharge peripheral
edema, yes
2.84 (1.07–7.61) 0.036
A backward model was used and only the final variables retained in
the model are presented. In the admission RDW model, the following
variables were tested: age, sex, atrial fibrillation (yes/no), LVEF,
peripheral edema (yes/no), interstitial edema on chest X-ray (yes/no),
pleural effusion on chest X-ray (yes/no), urea, creatinine, sodium,
potassium, hemoglobin, hematocrit, albumin, total protein, iron, ferritin,
transferrin saturation, and NT-pro BNP/100 (admission values were
used unless stated otherwise). In the discharge RDW model, the
following variables were tested: age, sex, atrial fibrillation (yes/no),
LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray
(yes/no), pleural effusion on chest X-ray (yes/no), admission RDW,
urea, creatinine, sodium, potassium, hemoglobin, hematocrit, albumin,
total protein, iron, ferritin, transferrin saturation, and NT-pro BNP/100
(discharge values were used whenever available). In the DRDWmodel,
the following variables were tested: age, sex, atrial fibrillation (yes/no),
LVEF, peripheral edema (yes/no), interstitial edema on chest X-ray
(yes/no), pleural effusion on chest X-ray (yes/no), admission and last
RDW, urea, creatinine, sodium, potassium, hemoglobin, hematocrit,
albumin, total protein, iron, ferritin, transferrin saturation, and NT-pro
BNP/100 (adjusted delta values were used whenever available). Bold,
significant value (P 0.05). D¼ adjusted delta (discharge–admission/
admission). NT-pro BNP¼N-terminal pro brain natriuretic peptide,
OR¼ odds ratio, RDW¼ red blood cell distribution width.
FIGURE 2. RDW¼ red blood cell distribution width, D¼ adjusted delta (discharge–admission/admission).
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FIGURE 3. Group 1: RDW discharge15% and DRDW0; group 2: RDW discharge15% and DRDW>0; group 3: RDW discharge>15
and DRDW 0; group 4: RDW discharge >15 and DRDW >0; group 5: DRDW 0 and DHemoglobin >0; group 6: DRDW 0 and
Dhemoglobin 0; group 7: DRDW >0 and Dhemoglobin >0; and group 8: DRDW >0 and Dhemoglobin 0. RDW¼ red blood cell
distribution width, D¼ adjusted delta (discharge–admission/admission).
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DISCUSSION
The present study shows that an enlarging RDW from
admission to discharge and elevated discharge RDW values
were independently associated with mid-term adverse events
over and above hemoconcentration (as measured by a change in
Hb during hospitalization). In addition, discharge RDW >15%
and DRDW>0, either alone or combined (especially the latter),
improved the prognostic model that included several well-
established prognostic variables plus hemoconcentration.
Except for hemoconcentration, these results were validated in
2 independent cohorts, and provide highly useful, simple,
pragmatic, and costless prognostic information with the poten-
tial to be used in daily clinical practice.
RDW as Prognostic Marker in Heart Failure and
Its Incremental Prognostic Utility
The prognostic value of RDW in HF is well established in
chronic HF. The CHARM (Candesartan in Heart Failure:
Assessment of Reduction in Mortality and Morbidity) program
included 2679 symptomatic chronic HF patients from North
TABLE 5. Net Reclassification Improvement and Integrated Discrimination Improvement for Predicting Composite Outcome at
180 days
Added Variable (s) Baseline Set of Variables NRI, % P-Value IDI, % P-Value
Discharge RDW (continuous) on top of age, LVEF, Hb,
pCr, and NT-pro BNP
17.9 (1.4 to 33.8) 0.080 3.6 (0.3 to 8.8) 0.027
Discharge RDW >15% 21.7 (0.1 to 37.1) 0.047 4.5 (0.1 to 13.3) 0.020
DRDW >0 29.6 (0.1 to 44.1) 0.053 5.6 (0.0 to 13.4) 0.050
Discharge RDW >15% and DRDW >0 23.1 (7.5 to 46.5) 0.013 8.2 (2.2 to 18.0) <0.001
DHemoglobin >0 (hemoconcentration) 8.7 (9.0 to 25.7) 0.276 1.8 (0.2 to 8.4) 0.106
Discharge RDW (continuous) on top of age, LVEF, Hb,
pCr, NT-pro BNP,
and hemoconcentration
16.3 (4.6 to 40.0) 0.105 3.3 (4.6 to 40.0) 0.052
Discharge RDW >15% 24.7 (1.2 to 40.1) 0.066 5.1 (0.0 to 13.7) 0.040
DRDW >0 30.0 (1.5 to 43.3) 0.060 4.7 (0.1 to 12.2) 0.033
Discharge RDW >15% and DRDW >0 18.3 (4.3 to 43.7) 0.012 7.8 (1.2 to 17.1) <0.001
The prediction models include age in years (<77 vs 77), left ventricular ejection fraction in % (<45 vs 45), hemoglobin in g/dL (<12 vs  12),
creatinine in mg/dL (<1.5 vs1.5), NT-pro BNP in pg/mL (<3500 vs3500) at admission and Dhemoglobin>0 (hemoconcentration). DHemoglobin
>0¼ hemoconcentration, that is, increase in hemoglobin fromadmission to discharge, andDhemoglobin0¼ no hemoconcentration, that is, decrease or
no increase in hemoglobin from admission to discharge. Bold, significant value (P 0.05). D¼ adjusted delta (discharge–admission/admission).
Hb¼ hemoglobin, IDI¼ integrated discrimination improvement, LVEF¼ left ventricular ejection fraction, NRI¼ net reclassification improvement, NT-
pro BNP¼N-terminal pro brain natriuretic peptide, pCr¼ plasma creatinine, RDW¼ red blood cell distribution width.
FIGURE 4. The prediction models include age in years (<77 vs 77), left ventricular ejection fraction in % (<45 vs 45), hemoglobin in
g/dL (<12 vs  12), creatinine in mg/dL (<1.5 vs 1.5), NT-pro BNP in pg/mL (<3500 vs  3500) at admission, and Dhemoglobin >0
(hemoconcentration).DHemoglobin>0¼hemoconcentration, that is, increase in hemoglobin from admission to discharge,D¼ adjusted
delta (discharge–admission/admission). Hb¼hemoglobin, IDI¼ integrated discrimination improvement, LVEF¼ left ventricular ejection
fraction, NRI¼net reclassification improvement, NT-pro BNP¼N-terminal pro brain natriuretic peptide, pCr¼plasma creatinine,
RDW¼ red blood cell distribution width.
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America in an analysis of 36 routine laboratory tests and their
association with mortality. Higher RDW showed the greatest
association with mortality and was among the most powerful
overall predictors, with only age and cardiomegaly showing a
better independent association with outcome. This finding was
then replicated in the Duke Databank, in which higher RDW
was strongly associated with ACM.6 In the ADHF setting the
evidence is scarcer, nonetheless in 628 patients hospitalized for
ADHF in Spain, a higher RDW at discharge (both continuous
and categorical) was significantly associated with increased
mortality independently of Hb value or anemia status. Addition-
ally, RDW was also found to be associated with elevated
troponin T, a marker of cardiomyocyte injury, and death in
HF populations.24 These studies used a single RDW value as
prognostic predictor. To the best of our knowledge, the present
study is the first to show that a rising RDW during hospital-
ization is independently associated with adverse events (hos-
pitalization and/or CVM) at 180 days. The predictive value of
rising RDW was also present in patients with discharge RDW
below the median of 15%. Of particular note, when rising RDW
and discharge RDW >15% were added to a prognostic model
including well-established HF prognostic markers (age, LVEF,
Hb, creatinine, NT-pro BNP, and hemoconcentration), the
capacity of the model to reclassify patients with and without
event was significantly improved. The incremental prognostic
utility of this finding merits serious consideration given its
simplicity, its readily availability to all clinicians, without
additional discomfort to the patients, and without cost escala-
tion. This finding is of utmost importance since current HF risk
prediction models do not take into account how individual
patient assessments occur in incremental steps and, further-
more, each additional diagnostic assessment may add additional
costs, complexity, and potential morbidity.25
RDW and Hemoconcentration
Ineffective decongestion is responsible for many (35%)
early readmissions,26 with a high burden both for the patient and
the health-care system.27 The lack of available data to help
clinicians in decongestion strategies is worrisome and requires
further investigation.28,29 More recently, hemoconcentration
has emerged as a possible target to assess decongestion in
HF,12–18 particularly when assessed both at admission and
discharge, since early improvements in congestion that are
not sustained through hospital stay are not likely to be associ-
ated with improved outcomes.30 The difference between admis-
sion and discharge Hb is likely to be a good candidate to assess
hemoconcentration.29 Moreover, our study showed that RDW is
inversely correlated with Hb and adds prognostic information in
addition to hemoconcentration, again with simple routine blood
count values. It is thus likely that RDW and Hb evolving in
opposite directions (increasing RDWand decreasing Hb) during
hospital stay portends a worse prognosis.
Potential Mechanisms
A rising RDW implies a reduction in structurally normal
hemoglobin molecules.3 In our series, patients with DRDW >0
were more likely to have more peripheral edema, lower sodium,
albumin, Hb and hematocrit levels, and higher NT-pro BNP at
discharge. A trend toward lower levels of serum iron during
hospitalization was also found in patients with DRDW >0. All
of these factors are associated with worse prognosis in HF.31,32
The underlying mechanism to these associations has yet to be
elucidated, although probably reflects a higher disease severity
incorporating several pathophysiological processes such as
nutritional deficiencies, inflammatory state, and renal dysfunc-
tion.6,33 In our study, RDW values are likely to be partially
explained by hemoglobin/hematocrit (both admission and dis-
charge RDW), transferrin saturation (discharge RDW), and by
the presence of peripheral edema (discharge RDW). Never-
theless, a large proportion of variability in RDW cannot be
explained by the several parameters tested herein, thus reinfor-
cing the possibility that RDW serves as an integrative measure
of several pathophysiological mechanisms such as anemia,
nutritional deficiencies, and possibly congestion. Recent data
have demonstrated that patients whose erythrocyte indices are
evolving toward an iron deficient picture (i.e., rising RDW and
falling mean corpuscular volume) have a higher risk of
mortality, independently of their anemia status.34 Nonetheless,
these data do not provide a clear basis for the prognostic
implication of a rising RDW during such a short period of time
(median length of stay in our dataset¼ 11 days), such that any
potential conclusive explanation at this point is merely specu-
lative.
Clinical Implications
Our data provide useful clinical information derived from
routine blood count without additional discomfort to the patient
or cost increase. The present findings show that an enlargement
in RDW from admission to discharge is associated with mid-
term adverse events, even more so if the patients exhibit RDW
>15% at discharge or no hemoconcentration (defined by Hb at
discharge – Hb at admission), thereby adding further prognostic
value to well established prognostic markers independently of
hemoconcentration. As a result, this simple measure should help
to identify patients likely to benefit from individualized strat-
egies, thereby enabling a closer follow-up and/or tailored
therapeutic strategies. This additional information particularly
relevant in patients with ADHF renders serial hemograms even
more useful during and possibly after ADHF hospitalization,
with both hemoconcentration and RDW changes being assessed
in routine clinical practice hemograms.
Limitations
Several limitations should be acknowledged in this study.
First, this is a 2-center, retrospective study (information was
prospectively recorded in the validation cohort) with potential
bias with regard to patient selection and information recording,
although the present data were monitored in both cohorts and
are consistent with previous studies in other fields as referenced
in the discussion. Thus, our findings are likely to be general-
izable. RDWwas necessarily prospectively measured within the
routine blood count (low risk of measurement bias – at least as
low as in routine practice), was available in all but few patients
(low risk of selection bias), and the used end-points were
objective and collected in a standardized fashion (low risk of
measurement bias). Our study thus avoided most pitfalls of
historical cohorts.35 In addition, patient treatment was not
tailored according to RDW values which further decreased
the risk of bias. As a consequence, the results here presented
are likely to reflect the prognostic value of RDW in daily
clinical practice. Second, the use of erythropoietin was not
investigated, and much of the data regarding iron parameters,
folate or vitamin B12, are lacking or absent (as in Paris cohort).
These values could provide further insight into the variation in
RDW as well as in results interpretation. Third, these cohorts do
not overlap the same patient-population, since Paris cohort
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subjects were likely to represent a less severe ADHF setting, as
those were patients admitted to the general urgency, they did not
necessarily have respiratory insufficiency, and had a much
lower 180-day mortality rate. Nonetheless, Paris RDW results
were also consistent with Porto results, suggesting that these
findings can be generalizable to less severe ADHF populations.
Fourth, we did not have discharge Hb in Paris cohort, hence
hemoconcentration was not determined in this population. Fifth,
discharge NP values could provide more accurate prognostic
information; however, we used admission NPs in the net
reclassification models due to the high percentage of missing
discharge values. Last, the low number of patients in the 4 group
categories reduces the precision of the estimated associations.
CONCLUSION
As validated in 2 independent ADHF cohorts, an enlarging
RDW during hospitalization for ADHF is associated with
adverse outcomes. The prognostic value of elevated discharge
RDW and rising RDW adds significant information (as assessed
by net reclassification methods) on top of well-established
prognostic variables (including hemoconcentration). These
inexpensive and easily available biomarkers could help refine
mid-term risk-stratification of patients admitted for ADHF.
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